GO
Loading...

Endo Health Solutions Inc

More

  • Aug 27- Repros Therapeutics Inc said its experimental drug to treat low testosterone was superior to a leading marketed gel and a placebo in the first of two identical studies. Patients who were given the drug, Androxal, experienced superiority in sperm concentration compared with those who used Abbvie Inc's AndroGel, said the company.

  • Aug 27- Repros Therapeutics Inc said its experimental drug to treat low testosterone was superior to a leading marketed gel and a placebo in two studies. Patients who were given the drug, Androxal, experienced superiority in sperm concentration compared with those who used Abbvie Inc's AndroGel, said the company.

  • July 31- Specialty healthcare company Endo International Plc reported a better-than-expected quarterly profit, helped by a 60 percent surge in U.S. generic sales, and raised its full-year forecast for the second time this year.

  • Endo tops Wall Street quarterly estimates Thursday, 31 Jul 2014 | 7:09 AM ET

    July 31- Specialty healthcare company Endo International Plc reported a better-than-expected quarterly profit, helped by a 60 percent rise in U.S. generic sales, and it raised its full-year forecast.

  • July 11- Medical device maker Covidien Plc said it recorded a pre-tax charge of about $180 million for the third quarter, related to litigation against some manufacturers of pelvic mesh products. Covidien said it was indemnifying the manufacturer on certain claims.

  • *Focus turns to earnings season. NEW YORK, July 7- U.S. stocks dipped on Monday, retreating from last week's record levels as investors hesitated to make big bets before the start of earnings season. The Russell 2000 fell 1.8 percent, its biggest percentage drop since April 25.

  • NEW YORK, July 7- U.S. stocks fell on Monday, retreating from record levels as investors hesitated to make big bets before the dawn of earnings season. The Russell 2000 fell 1.5 percent, on track for its biggest percentage drop since May 20.

  • *Focus turns to earnings season. NEW YORK, July 7- U.S. stocks fell on Monday, pulling back from record levels as investors held off from making big plays before the start of earnings season.

  • July 7- Endo International Plc and BioDelivery Sciences International Inc said their experimental pain drug was found effective in a second late-stage trial, taking the drug a step closer to a marketing approval.

  • July 7- Endo International Plc and BioDelivery Sciences International Inc said their experimental pain drug was found effective in a second late-stage trial. Biodelivery, which entered into an agreement with Endo to develop the drug for the treatment of chronic pain in January 2012, will receive a $10 million milestone payment from Endo as part of the deal.

  • July 7- Endo International Plc and BioDelivery Sciences International Inc said their experimental pain drug was found effective in a late-stage trial. The painkiller, BEMA buprenorphine, was being tested against a placebo in patients with pain severe enough to require around-the-clock, long-term opioid treatment.

  • FDA asks for wider warning on testosterone products Friday, 20 Jun 2014 | 8:31 AM ET

    The FDA said that while testosterone products already carry a warning about the risk of clots related to a condition that sometimes occurs with testosterone treatment, the latest reports of clots were unrelated to that condition, called polycythemia.

  • June 3- The city of Chicago has filed a lawsuit against five large narcotics makers alleging they contributed to the country's prescription drug epidemic by deceptively promoting their painkillers.

  • March 6- Endo International Plc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism.

  • Early movers: AOL, KORS, TMUS, CVS, AIG & more Tuesday, 5 Nov 2013 | 7:38 AM ET

    Some of the names on the move ahead of the open.

  • Check out which companies are making headlines after the bell Wednesday:

  • After-Hours Buzz: GPS, CRM, GRPN & More Thursday, 28 Feb 2013 | 3:40 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • After-Hours Buzz: CSTR, PRGS & More Thursday, 3 Jan 2013 | 4:39 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • After-Hours Buzz: Juniper, Boston Beer & More Wednesday, 12 Dec 2012 | 5:42 PM ET

    Check out which companies are making headlines after the bell Wednesday.

  • Shares of Samsung Electronics, which have surged almost 35 percent since the start of the year, closed at an all-time high on Thursday boosted by expectations that its smartphone business will continue to drive strong profit growth.